Switch theme
Sign up to access all valuation multiples
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients and over-the-counter drug products The company's segment include the Drug development segment and Other segments.
1998
14
LTM Revenue n/a
LTM EBITDA n/a
$221M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Easywell Biomedicals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Easywell Biomedicals achieved revenue of $16.3M and an EBITDA of $0.4M.
Easywell Biomedicals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Easywell Biomedicals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $8.2M | $16.3M | XXX | XXX | XXX |
| Gross Profit | $2.3M | $5.2M | XXX | XXX | XXX |
| Gross Margin | 28% | 32% | XXX | XXX | XXX |
| EBITDA | -$2.6M | $0.4M | XXX | XXX | XXX |
| EBITDA Margin | -31% | 2% | XXX | XXX | XXX |
| Net Profit | -$4.9M | -$4.4M | XXX | XXX | XXX |
| Net Margin | -59% | -27% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Easywell Biomedicals's stock price is TWD 59 (or $2).
Easywell Biomedicals has current market cap of TWD 7.2B (or $218M), and EV of TWD 7.3B (or $221M).
See Easywell Biomedicals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $221M | $218M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Easywell Biomedicals has market cap of $218M and EV of $221M.
Easywell Biomedicals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Easywell Biomedicals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Easywell Biomedicals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $221M | XXX | XXX | XXX |
| EV/Revenue | 13.6x | XXX | XXX | XXX |
| EV/EBITDA | 575.0x | XXX | XXX | XXX |
| P/E | -74.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -42.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEasywell Biomedicals's NTM/LTM revenue growth is n/a
Easywell Biomedicals's revenue per employee for the last fiscal year averaged $1.2M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Easywell Biomedicals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Easywell Biomedicals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Easywell Biomedicals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 99% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 2% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -115% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 51% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 68% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Easywell Biomedicals acquired XXX companies to date.
Last acquisition by Easywell Biomedicals was XXXXXXXX, XXXXX XXXXX XXXXXX . Easywell Biomedicals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Easywell Biomedicals founded? | Easywell Biomedicals was founded in 1998. |
| Where is Easywell Biomedicals headquartered? | Easywell Biomedicals is headquartered in Taiwan. |
| How many employees does Easywell Biomedicals have? | As of today, Easywell Biomedicals has 14 employees. |
| Is Easywell Biomedicals publicy listed? | Yes, Easywell Biomedicals is a public company listed on ROCO. |
| What is the stock symbol of Easywell Biomedicals? | Easywell Biomedicals trades under 1799 ticker. |
| When did Easywell Biomedicals go public? | Easywell Biomedicals went public in 2008. |
| Who are competitors of Easywell Biomedicals? | Similar companies to Easywell Biomedicals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Easywell Biomedicals? | Easywell Biomedicals's current market cap is $218M |
| What is the current revenue growth of Easywell Biomedicals? | Easywell Biomedicals revenue growth between 2023 and 2024 was 99%. |
| Is Easywell Biomedicals profitable? | Yes, Easywell Biomedicals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
